



01-23-02

N 0380

TRANSMITTAL LETTER			Case No. 10466/81
Serial No. 09/905,056	Filing Date July 12, 2001	Examiner To be assigned	Group Art Unit 1645
Inventor(s) Ashkenazi et al.			
Title of Invention SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME			

TO THE COMMISSIONER FOR PATENTS

Transmitted herewith is a Statement According to 37C.F.R. § 1.821(f); copy of Sequence Listing in computer readable form; copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures and return postcard.

Small entity status of this application under 37 CFR § 1.27 has been established by verified statement previously submitted.

A verified statement to establish small entity status under 37 CFR §§ 1.9 and 1.27 is enclosed.

Petition for a _____ month extension of time.

No additional fee is required.

The fee has been calculated as shown below:

	Claims Remaining After Amendment		Highest No. Previously Paid For	Present Extra
Total		Minus		
Indep.		Minus		
First Presentation of Multiple Dep. Claim				

Small Entity		Other Than Small Entity	
Rate	Add'l Fee	Rate	Add'l Fee
x \$9 =		x \$18 =	
x 42 =		x \$84 =	
+ \$140 =		+ \$280 =	
Total add'l fee	\$	Total add'l fee	\$

Please charge Deposit Account No. 23-1925 (BRINKS HOFER GILSON & LIONE) in the amount of \$_____. A duplicate copy of this sheet is enclosed.

A check in the amount of \$____ to cover the filing fee is enclosed.

The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 CFR § 1.16 and any patent application processing fees under 37 CFR § 1.17 associated with this communication or credit any overpayment to Deposit Account No. 23-1925. A duplicate copy of this sheet is enclosed.

I hereby petition under 37 CFR § 1.136(a) for any extension of time required to ensure that this paper is timely filed. Please charge any associated fees which have not otherwise been paid to Deposit Account No. 23-1925. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

Gregory M. Zinkl, Ph.D.
Registration No. 48,492
Agent for Applicant

BRINKS HOFER GILSON & LIONE
P.O. BOX 10395
CHICAGO, ILLINOIS 60610
(312) 321-4200

I hereby certify that this correspondence is being deposited with the United States Postal Service as express mail, label no. EL 562415125US, with sufficient postage, in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on 01/22/02

Date: 01/22/02

Signature: gmg



"Express Mail" mailing label number EL-562415125US

DEMAND
Date of Deposit: 01/22/02

Our Case No. 10466/81

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Ashkenazi et al.

Serial No. 09/905,056

Filing Date: July 12, 2001

For SECRETED AND
TRANSMEMBRANE
POLYPEPTIDES AND NUCLEIC
ACIDS ENCODING THE SAME

Examiner To be assigned

Group Art 1645

三

STATEMENT ACCORDING TO 37 C.F.R. § 1.821(f)

BOX SEQUENCE LISTING

Assistant Commissioner for Patents
Washington, D.C. 20231


Dear Sir:

Submitted herewith is a copy of the sequence listing in computer readable form. Applicants' representative states that the content of the attached compact disc copy in computer readable form of the Sequence Listing, submitted in accordance with 37 CFR 1.821(c) and (e), respectively, are identical.

Respectfully submitted,

Gregory M. Zirkl, Ph.D.
Registration No. 48,492
Agent for Applicant

BRINKS HOFER GILSON & LIONE
P.O. BOX 10395
CHICAGO, ILLINOIS 60610
(312) 321-4200



UNITED STATES PATENT AND TRADEMARK OFFICE


COMMISSIONER FOR PATENTS
 UNITED STATES PATENT AND TRADEMARK OFFICE
 WASHINGTON, D.C. 20231
 www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/905,056	07/12/2001	Avi Ashkenazi	P1618P2C44

CONFIRMATION NO. 2902

FORMALITIES LETTER

Paul E. Rauch, Ph.D.
 Brinks, Hofer, Gilson & Lione
 NBC Tower - Suite 3600
 455 Cityfront Plaza Drive
 Chicago, IL 60611-5599



BRINKS HOFER GILSON & LIONE
 RECEIVED
 OC000000007138813

Date Mailed: 11/29/2001

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
 CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
 DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A request to transfer the computer readable form from another application on file at the U.S. Patent and Trademark Office has been submitted as permitted by 37 C.F.R. 1.821(e). However, the request cannot be complied with since there is no compliant CRF present at the United States Patent and Trademark Office. Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.

M
 Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE